Xavier Boulenc

Evotec (United States) — United States

Pharmacology, Toxicology and Pharmaceutics · Life Sciences

18h-index1.1kcitations29works1.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Pharmacogenetics and Drug Metabolism(14), Drug Transport and Resistance Mechanisms(7), Analytical Methods in Pharmaceuticals(5), Computational Drug Discovery Methods(4), Pharmacological Effects and Toxicity Studies(4)

Publications29 total

A modeling-based framework to evaluate forgiveness of tuberculosis treatment in a BALB/c relapsing mouse model
Antimicrobial Agents and Chemotherapy·2026Open Access
A modeling-based framework to evaluate forgiveness of TB drug combinations in a BALB/c relapsing mouse model
2025· 2 citedOpen Access
Optimization of the Antibacterial Spectrum and the Developability Profile of the Novel-Class Natural Product Corramycin
Journal of Medicinal Chemistry·2023· 7 citedOpen Access
The antimalarial MMV688533 provides potential for single-dose cures with a high barrier to <i>Plasmodium falciparum</i> parasite resistance
Science Translational Medicine·2021· 49 citedOpen Access
Improving Prediction of Metabolic Clearance Using Quantitative Extrapolation of Results Obtained From Human Hepatic Micropatterned Cocultures Model and by Considering the Impact of Albumin Binding
Journal of Pharmaceutical Sciences·2018· 34 cited
Use of PBPK modeling for drug–drug interactions prediction of rifapentine on other drugs by induction of CYP3A4/5 and CYP2B6
Drug Metabolism and Pharmacokinetics·2018
IMI – oral biopharmaceutics tools project – evaluation of bottom-up PBPK prediction success part 1: Characterisation of the OrBiTo database of compounds
European Journal of Pharmaceutical Sciences·2016· 42 citedOpen Access
Evaluation of Normalization Methods To Predict CYP3A4 Induction in Six Fully Characterized Cryopreserved Human Hepatocyte Preparations and HepaRG Cells
Drug Metabolism and Disposition·2015· 25 cited
PBPK modeling of irbesartan: incorporation of hepatic uptake
Biopharmaceutics & Drug Disposition·2015· 18 cited
Physiologically Based Pharmacokinetic Modeling for Sequential Metabolism: Effect of CYP2C19 Genetic Polymorphism on Clopidogrel and Clopidogrel Active Metabolite Pharmacokinetics
Drug Metabolism and Disposition·2015· 57 cited
CYP3A4-based drug–drug interaction: CYP3A4 substrates’ pharmacokinetic properties and ketoconazole dose regimen effect
European Journal of Drug Metabolism and Pharmacokinetics·2014· 38 cited
Investigations with a humanised CYP3A4/3A7 mouse model
Toxicology Letters·2014
Metabolic-based drug-drug interactions prediction, recent approaches for risk assessment along drug development
Drug metabolism and drug interactions·2011· 20 cited
Clopidogrel Pharmacodynamics and Pharmacokinetics in the Fed and Fasted State: A Randomized Crossover Study of Healthy Men
The Journal of Clinical Pharmacology·2011· 16 cited
Effects of Omeprazole and Genetic Polymorphism of CYP2C19 on the Clopidogrel Active Metabolite
Drug Metabolism and Disposition·2011· 39 cited
B.13 In Vitro/In Vivo Correlation for Drug-Drug Interactions
2011· 2 cited
In Vitro/In Vivo Correlation for Drug–Drug Interactions
2010· 4 cited
Drug–Drug Interaction Studies
2010· 2 cited
Pharmacokinetic assessment of a five‐probe cocktail for CYPs 1A2, 2C9, 2C19, 2D6 and 3A
British Journal of Clinical Pharmacology·2009· 145 citedOpen Access
Quantitative Correlations Among CYP3A Sensitive Substrates and Inhibitors:Literature Analysis
Current Drug Metabolism·2007· 19 cited
page 1 of 2Next →

Frequent Co-authors

Gérard Fabre(7), Yves Berger(6), Claude Roques(5), H Joyeux(5), Sylvie Klieber(4), Martine Bourrié(3), Eric Sultan(3), Fabrice Hurbin(3), Olivier Nicolas(3), Olivier Barberan(3), Sylvie Sordello(3), Viviane Meunier(2), William R. Brian(2), Robert Van Horn(2), Yves Donazzolo(2), G Fabre(2), Nassim Djebli(2), Céline Ollier(2), Priscilla Brun(2), Hélène Vermet(2)